Phase 1/2 Dose-Rising, Safety, Tolerability and Efficacy Study of Topical SOR007 for Cutaneous Metastases
Phase of Trial: Phase I/II
Latest Information Update: 09 Feb 2018
At a glance
- Drugs Paclitaxel (Primary)
- Indications Cancer metastases; Skin cancer
- Focus Adverse reactions
- Sponsors Dfb Soria; Nanology
- 06 Feb 2018 Planned End Date changed from 1 Feb 2019 to 1 Apr 2019.
- 06 Feb 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Feb 2019.
- 06 Feb 2018 Status changed from not yet recruiting to recruiting.